Celyad Oncology Announces Receipt of Nasdaq Delisting Notice
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News:Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies.The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Ma...